Duke University

Redford B Williams

Marc G Caron

Raul R Gainetdinov

David A Schwartz

Martin Beaulieu

Tatiana D Sotnikova

Xiaodong Zhang

Ranga R Krishnan

Lauranell Burch

A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.

Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis

The present invention provides a method of screening subjects for disease risk. The method comprises determining the serotonin transporter gene promoter genotype of a subject. The serotonin transporter gene promoter genotype is used to indicate whether or not the subject is at increased risk of disease. The method is particularly adapted to screening for risk of disease in response to stress, and accordingly can be used to indicate interventions that manage stress, and hence reduce disease risk, in susceptible or higher-risk individuals.

Use of polymorphism of the serotonin transporter gene promoter as a predictor of disease risk

Growing community of inventors

Hillsborough, NC, United States of America

Redford B Williams